What treatments are available for wet AMD? 

Wet age-related macular degeneration (AMD) is an aggressive condition characterized by the growth of abnormal, leaky blood vessels underneath the macula. Unlike the “dry” form of the disease, which progresses slowly, wet AMD can lead to significant vision loss within weeks if left untreated. In the United Kingdom, the management of wet AMD is a clinical priority, with the National Health Service (NHS) providing access to highly effective sight saving treatments. The primary goal of these interventions is to stop the leakage of fluid and blood, flatten the macula, and stabilize or even improve the patient’s central vision. While the thought of regular medical procedures can be daunting, the modern treatment landscape for wet AMD is one of the most successful areas of ophthalmic medicine, offering hope for long term independence and sight preservation. 

What We’ll Discuss in This Article 

• The role of anti-VEGF injections as the primary treatment for wet AMD. 

• How medications like ranibizumab and aflibercept work to “dry out” the macula. 

• The “Treat and Extend” protocol used to personalize injection schedules. 

• The use of Photodynamic Therapy (PDT) and laser treatments in specific cases. 

• Emerging therapies and new drug delivery systems in the UK. 

• What to expect during a typical hospital treatment session. 

• The importance of timely intervention in the success of wet AMD care. 

The gold standard: Anti-VEGF injections 

The cornerstone of wet AMD treatment in the United Kingdom is the use of anti-vascular endothelial growth factor (anti-VEGF) medications. VEGF is a naturally occurring protein that promotes the growth of new blood vessels. In wet AMD, however, the body produces too much of this protein, leading to the creation of fragile, abnormal vessels that leak fluid and blood into the macula. Anti-VEGF drugs are designed to block this protein, effectively “starving” the abnormal vessels and causing them to shrink and stop leaking. 

In the UK, the most used anti-VEGF medications include ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo). These are administered via a small injection into the vitreous (the jelly like substance inside the eye). While the idea of an injection into the eye can be frightening, the procedure is performed under local anaesthetic and is typically very quick and painless. According to NICE guidance (NG82), these treatments are highly effective, with many patients experiencing a stabilization of their vision and a significant percentage seeing an improvement in their ability to read or recognize faces. 

Understanding the treatment pathway and “Loading Phase” 

Treatment for wet AMD is not a “one off” procedure but an ongoing management plan. When a patient is first diagnosed in a UK hospital clinic, they typically enter a “loading phase.” This usually involves a series of three or four injections administered approximately four weeks apart. The purpose of this initial phase is to aggressively tackle the fluid buildup and ensure the macula is as dry as possible. 

Following the loading phase, the ophthalmologist will use Optical Coherence Tomography (OCT) scans to monitor the macula’s response. If the scan shows that the fluid has gone, the doctor will move the patient into a maintenance phase. The goal of this phase is to find the longest possible time between injections while keeping the eye dry. This proactive approach is essential for preventing the “yo yo” effect where fluid returns and causes further damage between treatments. More information on the standard of care for injections is available on the NHS website. 

The “Treat and Extend” protocol 

In the United Kingdom, many eye clinics utilize a strategy known as “Treat and Extend.” This is a personalized approach designed to reduce the frequency of hospital visits while maintaining maximum protection for the macula. Under this regimen, the patient receives an injection at every visit, but the time between those visits is gradually extended by one or two weeks at a time, as long as the macula remains dry and stable. 

If the eye remains dry at a four-week interval, the next appointment is scheduled for six weeks, then eight, and so on, up to a maximum of 16 weeks for some newer medications. If at any point the OCT scan shows the fluid has returned, the interval is immediately shortened. This method is preferred in the UK because it prevents the fluid from recurring in the first place, rather than waiting for vision to drop before acting. This ensures that the patient receives a bespoke schedule tailored exactly to their eye’s unique biological needs. 

Photodynamic Therapy (PDT) and Laser treatments 

While anti-VEGF injections are the first choice for most patients, other treatments are sometimes used in specific or complex cases. Photodynamic Therapy (PDT) involves injecting a light sensitive drug (verteporfin) into the arm, which travels to the abnormal blood vessels in the eye. A “cold” laser is then shone into the eye to activate the drug, which causes the vessels to close up without damaging the surrounding retina. 

PDT is less common than it used to be, but it is still used in the UK for a specific type of AMD called Polypoidal Choroidal Vasculopathy (PCV) or when a patient does not respond well to injections alone. Thermal laser photocoagulation, which uses heat to “cauterize” leaking vessels, is now rarely used for AMD because it causes permanent blind spots in the area treated. However, it may still be an option for leaks located well away from the very centre of the macula. The Macular Society provides detailed resources on these alternative therapies. 

What to expect during a hospital treatment session 

A typical treatment session at an NHS eye clinic usually takes about one to two hours. Upon arrival, your vision will be checked on a letter chart, and you will have an OCT scan of your macula. The specialist will review these results to determine if an injection is needed. If you are proceeding with treatment, anaesthetic drops will be used to numb the surface of your eye, and an antiseptic solution (usually iodine) will be used to clean the area around the eye to prevent infection. 

The injection itself takes only a few seconds. Most patients describe it as a sensation of pressure or a slight “pinch” rather than actual pain. Following the procedure, you may see “floaters” or small bubbles in your vision for a day or two, and your eye might feel slightly gritty. You will be given instructions on what to look out for, such as signs of infection, and a follow up appointment will be scheduled. In the UK, patient safety during injections is a top priority, with strict protocols in place to minimize any risks. 

Summary of Wet AMD Treatment Options 

Treatment Type	How it Works	Frequency
Anti-VEGF Injections	Blocks proteins that grow leaky vessels	Every 4 to 16 weeks
Dual-Action Drugs	Blocks two proteins (VEGF and Ang-2)	Every 8 to 16 weeks
Photodynamic Therapy	Light-activated drug closes vessels	Specific cases only
Thermal Laser	Uses heat to seal leaking vessels	Rare; for off-centre leaks
Implantable Pumps	Slow-release reservoir of medication	Experimental / New
Gene Therapy	Modifies cells to produce medication	Experimental / Future

The importance of timing and the 14-day rule 

The effectiveness of all wet AMD treatments is heavily dependent on how quickly they are started. Once fluid begins to leak into the macula, it starts to damage the light sensitive cells. If this fluid is not removed quickly, it can turn into permanent scar tissue, at which point injections can no longer restore the lost vision. This is why the UK healthcare system emphasizes the “14-day rule.” 

According to national clinical standards, any patient suspected of having wet AMD should be seen by a specialist and start their treatment within two weeks of their initial referral. Adhering to this timeline is the single most important factor in achieving a good visual outcome. Patients who start treatment while their vision is still relatively good have the best chance of maintaining that level of sight for many years. 

Conclusion 

Treatments for wet AMD in the United Kingdom are highly effective and primarily focus on anti-VEGF injections to stop blood vessel leakage and preserve central sight. Through personalized schedules like the “Treat and Extend” protocol and the introduction of newer, longer lasting medications, clinicians can stabilize vision while reducing the number of hospital visits. While the condition requires long term management, early intervention remains the key to success. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot 

This article provides an evidence-based overview of the treatments available for wet AMD within the UK. The content was prepared by the Medical Content Team and reviewed by Dr. Rebecca Fernandez, a UK trained physician with experience in internal medicine and emergency care. All information is strictly aligned with the clinical pathways and “Treat and Extend” protocols established by the NHS and the National Institute for Health and Care Excellence (NICE) to ensure patient safety and accuracy.